Pharma major Zydus Cadila has filed an investigational new drug (IND) application seeking the Indian drug controller's permission for conducting clinical trials of its novel drug candidate for treating dyslipidemia and metabolic disorders.
The pre-clinical studies on its new molecular entity (NME) called ZYH7 have reported interesting and encouraging findings which indicate a novel molecule to treat Dyslipidemia, a disruption in the amount of lipids in the blood, and associated metabolic disorders, the Ahmedabad-based company said in a statement Thursday.
ZYH7 was conceptualised and developed at the Zydus Research Centre, which was set up in 2000. It has a dedicated team of over 230 research scientists working on its NME research programmes.
Starting with its first IND filing in 2005, Zydus has four INDs in various stages of clinical trials. NME - ZYH1 for treating dyslipidemia and ZYI1 for treating pain and inflammation are undergoing Phase II trials.
ZYH2 for treating diabetes and the novel CB-1 antagonist, ZYO1 for treating obesity, are undergoing Phase I trials.
Zydus Cadila chairman and managing director Pankaj Patel said: "We have been building a promising pipeline of new molecular entities at the Zydus Research Centre and ZYH7 is an important step in this direction. It reflects our commitment to new research initiatives that can help meet unmet healthcare needs in the focus areas of metabolic disorders, cardiovascular diseases, pain and inflammation."